Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Short-term Investments: 2024-2025

Historic Short-term Investments for Immunocore Holdings (IMCR) over the last 2 years, with Sep 2025 value amounting to $393.9 million.

  • Immunocore Holdings' Short-term Investments rose 8.37% to $393.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $393.9 million, marking a year-over-year increase of 8.37%. This contributed to the annual value of $364.6 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Immunocore Holdings' Short-term Investments stood at $393.9 million, which was down 0.24% from $394.9 million recorded in Q2 2025.
  • Over the past 5 years, Immunocore Holdings' Short-term Investments peaked at $394.9 million during Q2 2025, and registered a low of $354.6 million during Q2 2024.
  • For the 2-year period, Immunocore Holdings' Short-term Investments averaged around $372.0 million, with its median value being $364.1 million (2024).
  • Data for Immunocore Holdings' Short-term Investments shows a peak YoY increased of 11.36% (in 2025) over the last 5 years.
  • Immunocore Holdings' Short-term Investments (Quarterly) stood at $364.6 million in 2024, then increased by 8.37% to $393.9 million in 2025.
  • Its Short-term Investments stands at $393.9 million for Q3 2025, versus $394.9 million for Q2 2025 and $360.2 million for Q1 2025.